Last couple weeks, we've been reporting on the decrease in vaccine uptake and really the global vaccine markets and the pharmaceutical industries are seeing huge hits to the profit margins because the uptake is really just, it's going down after the COVID, after the pandemic response, the failed pandemic response.
But I want to report on something here we've never reported on before. What was a global flashing red light for the vaccine industry has just seen a pillar fall.
Never before has a recommended vaccine ever struggled to find recruits for its clinical studies and that just happened.
This is an exclusive from Reuters, Pfizer, BioNTech, HALT US COVID vaccine study after recruitment struggles.
They said the slow enrollment has caused them to halt this because they didn't have enough people to generate any relevant post-marketing data.
I don't even know what to say about this. I mean, this could be the fitting end for a COVID vaccine.
I do. This means that your polls and every one of these other articles that you've written saying that people don't care about this vaccine issue.
This is going to hurt the Trump administration, the midterms and all the things we're hearing.
Well, apparently enough people care about vaccines that you can't find enough people to line up for a trial now for a vaccine.
So where's the confidence there? Tell me those people.
I mean, and you're talking about the entire nation, they cannot find people enough to show up for a safety trial on a vaccine that's approved by the CDC.
Oh my God. Obviously, two different worlds are happening here. We're reporting on one of them.
And then there's what the rest of the television is trying to tell you in newspapers or trying to tell you is happening in the world.